Woodline Partners’s Supernus Pharmaceuticals SUPN Stock Holding History

Woodline Partners’s Portfolio SUPN Stock Details SUPN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$23.2M	Buy	+448,996	New	+$22.9M	0.09%	306
2025 Q4	–	Sell	-1,263,811	Closed	-$60.4M	–	1115
2025 Q3	$60.4M	Buy	1,263,811 +490,835	+63%	+$19.8M	0.28%	78
2025 Q2	$24.4M	Buy	+772,976	New	+$24.8M	0.13%	236
2025 Q1	–	Sell	-423,828	Closed	-$15.3M	–	1024
2024 Q4	$15.3M	Buy	423,828 +235,257	+125%	+$8.28M	0.1%	261
2024 Q3	$5.88M	Buy	+188,571	New	+$5.89M	0.05%	371
2024 Q2	–	Sell	-1,291,291	Closed	-$44M	–	662
2024 Q1	$44M	Buy	+1,291,291	New	+$38.4M	0.41%	68
2023 Q1	–	Sell	-105,878	Closed	-$3.78M	–	768
2022 Q4	$3.78M	Sell	105,878 -687,889	-87%	-$23.9M	0.05%	361
2022 Q3	$26.9M	Buy	793,767 +225,188	+40%	+$7.33M	0.38%	76
2022 Q2	$16.4M	Buy	568,579 +83,167	+17%	+$2.38M	0.25%	123
2022 Q1	$15.7M	Buy	+485,412	New	+$14.9M	0.25%	122
2021 Q4	–	Sell	-53,915	Closed	-$1.44M	–	783
2021 Q3	$1.44M	Buy	+53,915	New	+$1.45M	0.02%	470

Other funds holding SUPN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

NAMI

Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Woodline Partners's SUPN Position: Q1 2026 in Review

Woodline Partners opened a new position in Supernus Pharmaceuticals (SUPN) in Q1 2026: 448,996 shares worth $23.2M. The stake represents 0.09% of the portfolio and ranks #306 among its holdings. This is a return to the name: Woodline Partners previously reported a position in SUPN as recently as Q3 2025.

Woodline Partners first reported a position in SUPN in Q3 2021 and has held it in 11 quarters since. The position peaked at $60.4M in Q3 2025. 327 funds tracked by Wall St. Rank hold SUPN as of Q1 2026.

Woodline Partners held 448,996 shares of Supernus Pharmaceuticals worth $23.2M as of Q1 2026.
Supernus Pharmaceuticals was a new Woodline Partners position in Q1 2026.
Supernus Pharmaceuticals made up 0.09% of Woodline Partners's portfolio in Q1 2026, its #306 holding.
Woodline Partners first reported a position in Supernus Pharmaceuticals in Q3 2021 and has held it in 11 quarters since.
Woodline Partners's Supernus Pharmaceuticals position peaked at $60.4M in Q3 2025.
327 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q1 2026.

Based on Woodline Partners's 13F filing for Q1 2026, filed 15 May 2026.